🔗 Share this article The United States and United Kingdom Conclude Tariff-Free Agreement on Prescription Drugs. Representative image of pharmaceutical shipments. The UK and US have signed a significant bilateral deal that will keep zero duties on UK medicine products entering the American market. Key Provisions of the Accord As part of the deal, the UK has committed to raise spending on medicines through the NHS. This commitment ensures that duties on these crucial goods will remain at zero for a timeframe of 36 months. This deal is in response to earlier warnings to hike import taxes on branded drug imports, with figures floated reaching one hundred percent. "This agreement between the Britain reinforces the global environment for innovative medicines and brings much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement said. Trade Importance Pharmaceuticals represent one of the UK's biggest export categories to the America, which is clearly the biggest buyer for major companies like GSK and AstraZeneca. Statistics show that in the 12 months prior to last September, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount made up a significant portion of British export trade in that period. "This guarantee safeguards work, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented. Detailed British Pledges The deal entails several key pledges from the British government: Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%. Increased NHS Spending: There is a target to raise overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period. Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments exceeded twenty percent. Recent Tensions This agreement comes amid a protracted row between the sector and the ministers over drug pricing and regulatory access. The disagreement were heightened by assertions that US consumers were charged a premium for the equivalent treatments than patients in the Britain and the EU. In recent months, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar expansions have been announced toward US facilities. One official stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
Representative image of pharmaceutical shipments. The UK and US have signed a significant bilateral deal that will keep zero duties on UK medicine products entering the American market. Key Provisions of the Accord As part of the deal, the UK has committed to raise spending on medicines through the NHS. This commitment ensures that duties on these crucial goods will remain at zero for a timeframe of 36 months. This deal is in response to earlier warnings to hike import taxes on branded drug imports, with figures floated reaching one hundred percent. "This agreement between the Britain reinforces the global environment for innovative medicines and brings much-needed balance to U.S.–U.K. pharmaceutical trade," an announcement said. Trade Importance Pharmaceuticals represent one of the UK's biggest export categories to the America, which is clearly the biggest buyer for major companies like GSK and AstraZeneca. Statistics show that in the 12 months prior to last September, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount made up a significant portion of British export trade in that period. "This guarantee safeguards work, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented. Detailed British Pledges The deal entails several key pledges from the British government: Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%. Increased NHS Spending: There is a target to raise overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period. Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments exceeded twenty percent. Recent Tensions This agreement comes amid a protracted row between the sector and the ministers over drug pricing and regulatory access. The disagreement were heightened by assertions that US consumers were charged a premium for the equivalent treatments than patients in the Britain and the EU. In recent months, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar expansions have been announced toward US facilities. One official stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its resources over the last ten years.